ASCO 2011 Roundup

June 2011
BioWorld Today;6/7/2011, Vol. 22 Issue 109, p3
The article focuses on a report by Agenus Inc. during the 2011 annual meeting of the American Society of Clinical Oncology (ASCO), that its Phase II trial revealed that its Series G-200 vaccine could give patients with glioblastoma multiforme a median overall survival of 11 months.


Related Articles

  • In spite of criticism, Lilly saves lives. Schenck, Steven J. // Indianapolis Business Journal;3/30/2009, Vol. 30 Issue 4, p11A 

    The author shares his views on the success of Indianapolis, Indiana-based drug company Eli Lilly & Co. in introducing the trial drug Enzastaurin, which has saved the life of his wife. He narrates how his wife suffering from glioblastoma was cured by a clinical trial using the drug. The author...

  • 1-2 Punch Inhibits Brain Cancer Recurrence.  // BioWorld Today;8/23/2010, Vol. 21 Issue 162, Special section p1 

    The article reports on a study by University of Massachusetts researchers which indicates the effectiveness of a combination of temozolomide and a Notch inhibitor in preventing the recurrence of glioblastoma multiforme.

  • Brain tumor and Gliadel wafer treatment. Panigrahi, M.; Das, P. K.; Parikh, P. M. // Indian Journal of Cancer;Jan-Mar2011, Vol. 48 Issue 1, p11 

    Glioblastoma is a rapidly progressive and extremely fatal form of brain tumor with poor prognosis. It is the most common type of primary brain tumor. Even with the most aggressive conventional treatment that comprises surgery followed by radiotherapy and chemotherapy, most patients die within a...

  • Cytoreductive surgery of glioblastoma as the key to successful adjuvant therapies: new arguments in an old discussion. Stummer, Walter; van denBent, Martin J.; Westphal, Manfred // Acta Neurochirurgica;Jun2011, Vol. 153 Issue 6, p1211 

    Background: This article discusses data from 3 randomized phase 3 trials, supporting a role for surgery in glioblastoma. Methods: Data were reviewed by extent of resection during primary surgery from the ALA-Glioma Study (fluorescence-guided versus conventional resection), the BCNU wafer study...

  • How surgery, radiotherapy and chemotherapy each contribute to the outcome of treatment for adult patients with Glioblastoma? Rojas Villabona, Álvaro // Revista Médicas UIS;2012, Vol. 25 Issue 3, p209 

    Introduction: glioblastoma is a common condition associated with high morbidity and mortality; most of newly diagnosed patients will die within two years. The current standard therapy is maximal surgical resection followed by radiotherapy plus concomitant and adjuvant temozolamide. Objective: it...

  • Northwest's DCVax-L Adds UK Sites in Phase III GBM Program. Shaffer, Catherine // BioWorld Today;8/24/2012, Vol. 23 Issue 165, p1 

    The article reports on the 300-patient Phase III trial of Bethesda, Maryland-based Northwest Biotherapeutics Inc.'s DCVax-L for glioblastoma multiforme (GBM), approved by the Great Britain Medicines and Healthcare Products Regulatory Agency. It describes the composition of the product and the...

  • Phase III Efficacy Failure Sinks Another Glioblastoma Drug. Powers, Marie // BioWorld Today;2/26/2013, Vol. 24 Issue 37, p1 

    The artcile reports on the Phase III trial conducted by EMD Serono Inc. which shows the failure of cilengtide to improve overall survival (OS) in glioblastoma patients with methylated O6- methylguanine-DNA methyltransferase (MGMT) gene promoter status. It indicates that the adverse events...

  • Erratum to: Phase I trial of verubulin (MPC-6827) plus carboplatin in patients with relapsed glioblastoma multiforme. Grossmann, Kenneth; Colman, Howard; Akerley, Wallace; Glantz, Michael; Matsuoko, Yuko; Beelen, Andrew; Yu, Margaret; Groot, John; Aiken, Robert; Olson, Jeffrey; Evans, Brent; Jensen, Randy // Journal of Neuro-Oncology;Jun2013, Vol. 113 Issue 1, p151 

    No abstract available.

  • The role of targeted therapies in the management of progressive glioblastoma. Olson, Jeffrey; Nayak, Lakshmi; Ormond, D.; Wen, Patrick; Kalkanis, Steven; Ryken, Timothy // Journal of Neuro-Oncology;Jul2014, Vol. 118 Issue 3, p557 

    Question: What is the influence of targeted medical therapies on disease control and survival in the adult patient with progressive glioblastoma? Targeted population: This recommendation applies to adult patients with progressive glioblastoma Recommendations: Level III Treatment with bevacizumab...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics